NYSE:PFEPharmaceuticals
Pfizer's BRAFTOVI Trial Win Adds Weight To Undervalued Oncology Story
Pfizer (NYSE:PFE) reported positive pivotal Phase 3 trial results for BRAFTOVI in combination with cetuximab and FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer.
The combination showed a significant improvement in progression free survival in untreated patients with this mutation.
Pfizer plans to share the data with the FDA for potential regulatory approval, aiming to expand its oncology portfolio.
For you as an investor, this update fits into Pfizer's push to grow its oncology...